The cost effectiveness of palivizumab in congenital heart disease: a review of the current evidence

References

• Simoes EA. Respiratory syncytial virus infection. Lancet 1999;354:847-52
   PubMed Web of Science ®Google Scholar
• Glezen WP, Taber LH, Frank AL, et al. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986;140:543-6
   PubMedGoogle Scholar
• Shay DK, Holman RC, Newman RD, et al. Bronchiolitis-associated hospitalizations among US children, 1980-1996. Jama 1999;282:1440-6
   PubMed Web of Science ®Google Scholar
• Kristensen K, Stensballe LG, Bjerre J, et al. Risk factors for respiratory syncytial virus hospitalisation in children with heart disease. Arch Dis Child 2009;94:785-9
   PubMedGoogle Scholar
• Altman CA, Englund JA, Demmler G, et al. Respiratory syncytial virus in patients with congenital heart disease: a contemporary look at epidemiology and success of preoperative screening. Pediatr Cardiol 2000;21:433-8
   PubMed Web of Science ®Google Scholar
• MacDonald NE, Hall CB, Suffin SC, et al. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med 1982;307:397-400
   PubMed Web of Science ®Google Scholar
• Feltes TF, Sondheimer HM, Tulloh RM, et al. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediatr Res 2011;70:186-91
   PubMed Web of Science ®Google Scholar
• Feltes TF, Sondheimer HM. Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease. Expert Opin Biol Ther 2007;7:1471-80
   PubMed Web of Science ®Google Scholar
• Khongphatthanayothin A, Wong PC, Samara Y, et al. Impact of respiratory syncytial virus infection on surgery for congenital heart disease: postoperative course and outcome. Crit Care Med 1999;27:1974-81
   PubMed Web of Science ®Google Scholar
• Moler FW, Khan AS, Meliones JN, et al. Respiratory syncytial virus morbidity and mortality estimates in congenital heart disease patients: a recent experience. Crit Care Med 1992;20:1406-13
   PubMed Web of Science ®Google Scholar
• Navas L, Wang E, de Carvalho V, et al. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada. J Pediatr 1992;121:348-54
   Google Scholar
• Welliver RCSr, Checchia PA, Bauman JH, et al. Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children. Curr Med Res Opin 2010;26:2175-81
   PubMed Web of Science ®Google Scholar
• Cohen SA, Zanni R, Cohen A, et al. Palivizumab use in subjects with congenital heart disease: results from the 2000-2004 Palivizumab Outcomes Registry. Pediatr Cardiol 2008;29:382-7
   PubMed Web of Science ®Google Scholar
• Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143:532-40
   PubMed Web of Science ®Google Scholar
• Meissner HC. Selected populations at increased risk from respiratory syncytial virus infection. Pediatr Infect Dis J 2003;22:S40-4; discussion S44–5
   Google Scholar
• IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998;102:531-7
   Web of Science ®Google Scholar
• American Academy of Pediatrics. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003;112:1442-6
   PubMed Web of Science ®Google Scholar
• Smart KA, Paes BA, Lanctot KL. Changing costs and the impact on RSV prophylaxis. J Med Econ 2010;13:705-8
   PubMedGoogle Scholar
• Ofman JJ, Sullivan SD, Neumann PJ, et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm 2003;9:53-61
   PubMedGoogle Scholar
• Bank of Canada. 10-year currency converter. Available online at: http://www.bankofcanada.ca/en/rates/exchform.html. Accessed June 25, 2012
   Google Scholar
• United States Department of Labor CPI Inflation Calculator. Available online at: http://www.bls.gov/data/inflation_calculator.htm. Accessed June 25, 2012
   Google Scholar
• Nuijten M, Lebmeier M, Wittenberg W. Cost effectiveness of palivizumab in children with congenital heart disease in Germany. J Med Econ 2009;12:301-8
   PubMedGoogle Scholar
• Yount LE, Mahle WT. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics 2004;114:1606-11
   PubMed Web of Science ®Google Scholar
• Harris KC, Anis AH, Crosby MC, et al. Economic evaluation of palivizumab in children with congenital heart disease: a Canadian perspective. Can J Cardiol 2011;27:523.e11-523.e15
   Google Scholar
• Rackham OJ, Thorburn K, Kerr SJ. The potential impact of prophylaxis against bronchiolitis due to the respiratory syncytial virus in children with congenital cardiac malformations. Cardiol Young 2005;15:251-5
   PubMed Web of Science ®Google Scholar
• Nuijten MJ, Wittenberg W, Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Pharmacoeconomics 2007;25:55-71
   PubMed Web of Science ®Google Scholar
• Resch B, Gusenleitner W, Nuijten MJ, et al. Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria. Clin Ther 2008;30:749-60
   PubMed Web of Science ®Google Scholar
• Resch B, Sommer C, Nuijten MJ, et al. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria. Pediatr Infect Dis J 2012;31:e1-8
   PubMed Web of Science ®Google Scholar
• Nuijten M, Lebmeier M, Wittenberg W. Cost effectiveness of palivizumab for RSV prevention in high-risk children in the Netherlands. J Med Econ 2009;12:291-300
   PubMedGoogle Scholar
• Wang D, Cummins C, Bayliss S, et al. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Health Technol Assess 2008;12:iii, ix-x, 1–86
   Google Scholar
• Hampp C, Kauf TL, Saidi AS, et al. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications. Arch Pediatr Adolesc Med 2011;165:498-505
   PubMed Web of Science ®Google Scholar
• Botto LD, Correa A, Erickson JD. Racial and temporal variations in the prevalence of heart defects. Pediatrics 2001;107:E32
   PubMed Web of Science ®Google Scholar
• Allen HD. Exercise testing. Moss and Adams' heart disease in infants, children and adolescents: including the fetus and young adult. Baltimore, MD: Lippincott Williams & Wilkins, 2008
   Google Scholar
• Tulloh R, Marsh M, Blackburn M, et al. Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. Cardiol Young 2003;13:420-3
   PubMed Web of Science ®Google Scholar
• Joint Formulary Committee. British National Formulary. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2003
   Google Scholar
• Langley J. Use of palivizumab in children with congenital heart disease. The Canadian Paediatric Society. Paediatr Child Health 2003;8:631-6
   PubMedGoogle Scholar
• Wren C, O'Sullivan JJ. Survival with congenital heart disease and need for follow up in adult life. Heart 2001;85:438-43
   PubMed Web of Science ®Google Scholar
• Groothuis JR, Simoes EA, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med 1993;329:1524-30
   PubMed Web of Science ®Google Scholar
• The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997;99:93-9
   PubMed Web of Science ®Google Scholar
• Duppenthaler A, Ammann RA, Gorgievski-Hrisoho M, et al. Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease. Arch Dis Child 2004;89:961-5
   PubMed Web of Science ®Google Scholar
• Greenough A, Alexander J, Burgess S, et al. Health care utilisation of prematurely born, preschool children related to hospitalization for RSV infection. Arch Dis Child 2004;89:673-8
   PubMed Web of Science ®Google Scholar